The latter are exemplified by RyR1 mutation-related congenital myopathies or malignant hyperthermia susceptibility resulting from clinical loss-of-function, RyR1 Ca2+-binding site mutations (Witherspoon and Meilleur, 2016). This evidence concerns the gene RYR1 and Malignant hyperthermia.